Hospira Reaches New 12-Month High at $50.69 (HSP)
Hospira (NYSE:HSP)’s share price hit a new 52-week high on Friday , American Banking & Market News reports. The company traded as high as $50.69 and last traded at $50.61, with a volume of 528,566 shares traded. The stock had previously closed at $50.03.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Hospira from a “neutral” rating to an “outperform” rating in a research note on Thursday, May 29th. They now have a $58.00 price target on the stock. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of Hospira in a research note on Thursday, May 1st. They now have a $48.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated a “sell” rating on shares of Hospira in a research note on Thursday, May 1st. They now have a $35.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $44.29.
The stock has a 50-day moving average of $46.86 and a 200-day moving average of $43.36. The company has a market cap of $8.488 billion and a P/E ratio of 61.61.
Hospira (NYSE:HSP) last announced its earnings results on Wednesday, April 30th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.11. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the company posted $0.52 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, analysts predict that Hospira will post $2.19 earnings per share for the current fiscal year.
Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.